Patent US4069102A successfully refreshed from Google Patents.
← Back to Patent Explorer
US4366244A Expired / Lapsed US ⏱️ 0.0 years remaining

Method for measuring serum cholesterol

Assignee: FIS FOURNIER INNOVATION ET SYNERGIE A 38 AVENUE HOCHE 75008 PARIS FRANCE SA
•
Filing: 1981-03-16
•
Granted: 1982-12-28
•
Expires: 2001-03-16
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract The invention relates to methods for measuring cholesterol of various fractions of seric lipoproteins, the methods comprising the separation of said fractions of lipoproteins by means of a lectin capable of precipitating the LDL and VLDL fractions, then measuring the amount of cholesterol in the precipitate and in the remaining solution.

Inventors

  • 👤 Marc Pascal

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-10-23 19:01
CPC Classifications
C; C12; C12Q; C12Q1/00; C12Q1/60; G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/92; G01N2800/00; G01N2800/04; G01N2800/044; Y; Y10; Y10S; Y10S210/00; Y10S210/902; Y10S210/903; Y10S210/905; Y10S435/00; Y10S435/81

Claims Analysis

Total Claims: 25
Claim 1
Independent Claim 160 words
A method of determining the cholesterol content of LDL and VLDL lipoproteins in a serum containing the same together with HDL lipoproteins which comprises: (A) contacting the serum with a solution of concanavalin A wherein the concentration of concanavalin A in said solution is less than 10 mg/ml calculated with respect to undiluted serum, in such an amount as to selectively precipitate substantially all of the LDL and VLDL lipoproteins contained in said serum but to leave HDL lipoproteins in the resultant supernatant liquid; (B) separating said precipitate from said supernatant liquid; (C) treating said precipitate so as to denature proteins therein which interfere with measurement of the cholesterol content of lipoprotein in said precipitate; (D) eliminating serum constituents such as bilirubin and urea derivatives which are liable to interfere with the measurement of the content of cholesterol by contacting the cholesterol in the precipitate with a selective solubilizing agent; and (E) determining the cholesterol content of the isolated precipitate.
Claim 2
Independent Claim 160 words
A method of determining the cholesterol content of LDL and VLDL lipoproteins in a serum containing the same together with HDL lipoproteins which comprises: (A) contacting the serum with a solution of concanavalin A wherein the concentration of concanavalin A in said solution is less than 10 mg/ml calculated with respect to undiluted serum, in such an amount as to selectively precipitate substantially all of the LDL and VLDL lipoproteins contained in said serum but to leave HDL lipoproteins in the resultant supernatant liquid; (B) separating said precipitate from said supernatant liquid; (C) treating said precipitate so as to denature proteins therein which interfere with measurement of the cholesterol content of lipoprotein in said precipitate; (D) eliminating serum constituents such as bilirubin and urea derivatives which are liable to interfere with the measurement of the content of cholesterol by contacting the cholesterol in the precipitate with a selective solubilizing agent; and (E) determining the cholesterol content of the isolated precipitate.
Claim 3
Dependent Claim 19 words
A process according to claim 1 wherein said concanavalin A is added in the form of an aqueous solution.
Claim 4
Dependent Claim 25 words
A process according to claim 2, wherein said aqueous solution contains 0.8 mg/ml to 3 mg/ml of concanavalin A calculated with respect to undiluted serum.
Claim 5
Dependent Claim 25 words
A process according to claim 1, wherein there is added to serum to which concanavalin A has been added a neutral polar and non-tensioactive polymer.
Claim 6
Dependent Claim 27 words
A process according to claim 4, wherein said polymer is employed in an amount of 0.5 to 5 weight percent based upon the weight of said serum.
Claim 7
Dependent Claim 27 words
A process according to claim 4, wherein said polymer is a polyethylene glycol or polypropylene glycol polymer, the average molecular weight of which is 200 to 200,000.
Claim 8
Dependent Claim 17 words
A process according to claim 1 wherein the denaturation is effected by means of an acid solution.
Claim 9
Dependent Claim 21 words
A process according to claim 1, wherein said selective solubilizing agent comprises a solution of uranyl acetate in glacial acetic acid.
Claim 10
Dependent Claim 24 words
A process according to claim 1, wherein the cholesterol content of the precipitate is determined by means comprising reacting the cholesterol with an enzyme.
Claim 11
Dependent Claim 39 words
A process according to claim 9, wherein the enzymatic determination of cholesterol content comprises hydrolyzing the cholesterol esters contained therein with cholesterol esterase, oxidizing cholesterol with cholesterol oxidates and titrating H 2 O 2 resulting from the oxidation reaction.
Claim 12
Dependent Claim 31 words
A process according to claim 1, wherein the precipitate is dissolved by means of a glucoside solution and thereafter cholesterol content is determined by means comprising reacting cholesterol with an enzyme.
Claim 13
Dependent Claim 40 words
A process according to claim 1, wherein a cholesterol fraction is isolated and the content of cholesterol is determined by colorimetry using a coloring agent consisting of orthophthaldialdehyde in solution in a mixture of glacial acetic acid and sulphydric acid.
Claim 14
Independent Claim 158 words
A method of determining the cholesterol content of HDL lipoprotein in a serum containing the same together with LDL and VLDL lipoproteins which comprises: (A) contacting the serum with a solution of concanavalin A wherein the concentration of concanavalin A in said solution is less than 10 mg/ml calculated with respect to undiluted serum, in such an amount as to selectively precipitate substantially all of the LDL and VLDL lipoproteins in said serum but to leave HDL lipoproteins in the resulting supernatant liquid; (B) separating said supernatant liquid from said precipitate; (C) treating said supernatant liquid so as to denature proteins therein which interfere with measurement of the cholesterol content of lipoprotein in said supernatant liquid; (D) eliminating serum constituents such as bilirubin and urea derivatives which are liable to interfere with the measurement of the content of cholesterol in the supernatant liquid with a selective solubilizing agent; and (E) determining the cholesterol content of the supernatant liquid.
Claim 15
Independent Claim 158 words
A method of determining the cholesterol content of HDL lipoprotein in a serum containing the same together with LDL and VLDL lipoproteins which comprises: (A) contacting the serum with a solution of concanavalin A wherein the concentration of concanavalin A in said solution is less than 10 mg/ml calculated with respect to undiluted serum, in such an amount as to selectively precipitate substantially all of the LDL and VLDL lipoproteins in said serum but to leave HDL lipoproteins in the resulting supernatant liquid; (B) separating said supernatant liquid from said precipitate; (C) treating said supernatant liquid so as to denature proteins therein which interfere with measurement of the cholesterol content of lipoprotein in said supernatant liquid; (D) eliminating serum constituents such as bilirubin and urea derivatives which are liable to interfere with the measurement of the content of cholesterol in the supernatant liquid with a selective solubilizing agent; and (E) determining the cholesterol content of the supernatant liquid.
Claim 16
Dependent Claim 16 words
A process according to claim 13, wherein said solution of concanavalin A is an aqueous solution.
Claim 17
Dependent Claim 21 words
A process according to claim 14, wherein the aqueous solution contains between about 0.8 mg/ml and 3 mg/ml of concanavalin A.
Claim 18
Dependent Claim 26 words
A process according to claim 13, wherein there is added to the serum to which concanavalin A has been added a neutral, polar and nontensioactive polymer.
Claim 19
Dependent Claim 27 words
A process according to claim 16, wherein said polymer is employed in an amount of 0.5 to 5 weight percent based upon the weight of said serum.
Claim 20
Dependent Claim 28 words
A process according to claim 16, wherein said polymer is a polyethylene glycol or a polypropylene glycol polymer, the average molecular weight of which is 200 to 20,000.
Claim 21
Dependent Claim 17 words
A process according to claim 13, wherein the denaturation is effected by means of an acid solution.
Claim 22
Dependent Claim 21 words
A process according to claim 13, wherein said selective solubilizing agent comprises a solution of uranyl acetate in glacial acetic acid.
Claim 23
Dependent Claim 24 words
A process according to claim 13, wherein the cholesterol content of the supernatant liquid is determined by means comprising reacting cholesterol with an enzyme.
Claim 24
Dependent Claim 39 words
A process according to claim 21, wherein the enzymatic determination of cholesterol content comprises hydrolyzing the cholesterol esters contained therein with cholesterol esterase, oxidizing cholesterol with cholesterol oxidates and titrating H 2 O 2 resulting from the oxidation reaction.
Claim 25
Dependent Claim 40 words
A process according to claim 13, wherein a cholesterol fraction is isolated and the content of cholesterol is determined by colorimetry using a coloring agent consisting of orthophthaldialdehyde in solution in a mixture of glacial acetic acid and sulphydric acid.

References Cited (Backward Citations)

US3839314A Cited
US3902964A Cited
US3955125A Cited
US4148869A Cited
US4096136A Cited
US4110077A Cited
US4126416A Cited
US4188188A Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1985-12-27 1986-06-28 1986-12-28 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1989-12-27 1990-06-28 1990-12-28 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 1993-12-27 1994-06-28 1994-12-28 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag